Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb;17(2):173-175.
doi: 10.2215/CJN.16591221.

Induction Therapy in Immunologically Well-Matched Recipients: Less May Be More

Vishnu S Potluri  1 , Roy D Bloom
Affiliations
Editorial

Induction Therapy in Immunologically Well-Matched Recipients: Less May Be More

Vishnu S Potluri et al. Clin J Am Soc Nephrol. 2022 Feb.
No abstract available

Keywords: induction therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Increasing use of induction therapy for low–immunologic risk patients in the United States. This image was restricted to patients who received a zero-HLA mismatch transplant, had 0% calculated panel reactive antibodies at transplant, received a kidney alone transplant, and did not receive a prior transplant. FDA, Food and Drug Administration; IL-2RA, IL-2 receptor antagonist.
See this image and copyright information in PMC

Comment on

References

    1. Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, Robinson A, Foutz J, Booker SE, Israni AK, Hirose R, Snyder JJ: OPTN/SRTR 2019 annual data report: Kidney. Am J Transplant 21[Suppl 2]: 21–137, 2021 - PubMed
    1. Wiseman AC: Induction therapy in renal transplantation: Why? What agent? What dose? We may never know. Clin J Am Soc Nephrol 10: 923–925, 2015 - PMC - PubMed
    1. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group : Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355: 1967–1977, 2006 - PubMed
    1. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, Charpentier B, Touchard G, Berthoux F, Merville P, Ouali N, Squifflet JP, Bayle F, Wissing KM, Hazzan M: Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 20: 1385–1392, 2009 - PMC - PubMed
    1. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM; Kidney Disease: Improving Global Outcomes : KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int 77: 299–311, 2010 - PubMed

Publication types